Biomarin Pharmaceutical Inc (BMRN)

neg -1.60
Today's Range: 81.85 - 84.02 | BMRN Avg Daily Volume: 1,525,100
Last Update: 10/21/16 - 2:50 PM EDT
Volume: 646,072
YTD Performance: -19.63%
Open: $84.00
Previous Close: $84.20
52 Week Range: $62.12 - $148.92
Oustanding Shares: 163,465,821
Market Cap: 13,959,981,113
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 11 11 12
Moderate Buy 2 2 2 2
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.27 1.29 1.29 1.27
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -25.79
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-25.79 0.00 29.40
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-10.20% -18.98% 26.88%
Revenue 18.50 0.80 0.21
Net Income 0.00 0.50 0.00
EPS 0.00 0.10 0.00
Earnings for BMRN:
Revenue 0.89B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $-0.39 $-0.47 $-0.25 $-1.11
Number of Analysts 13 11 7 13
High Estimate $-0.22 $-0.39 $-0.09 $0.11
Low Estimate $-0.51 $-0.61 $-0.40 $-1.81
Prior Year $-0.60 $-0.58 $-1.58 $-0.25
Growth Rate (Year over Year) 34.23% 18.34% 84.18% -345.54%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Overall, this is still a good environment for stock picking.
They're striking while the iron is hottest to raise money, reduce debt.
That may be the best way to get through the notorious month of August.
All of these add up to a level of insecurity on the part of sidelined money.

Bret Jensen Reporting for Duty Real Money Pro($)

Good morning -- Bret Jensen here! As always, it's good to be standing in for Doug Kass.
The big downtrend line was broken decisively.
BMRN could re-base in the weeks and months ahead as downside looks limited. 
Also, Pfizer-Allergan deal clears another hurdle.
Once again, buyers are going for the gusto.

Columnist Conversations

we saw decent numbers from mr softie, our calls up nicely. We'll roll up. SOLD MSFT DEC 55 CAL...
we have a stellar winner here, will sell it and move on. SECOND this week! SOLD NFLX NOV 120 CALL AT ...
UK-based Manpower Group (MAN) reported better than expected Q3 earnings, at $1.87 versus a $1.72 estimate. ...
Join me for a very exclusive webinar with the amazing Mark Mahaney, from RBC Capital Markets.  Mark is on...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.